NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, Nov. 08, 2018 (GLOBE NEWSWIRE) — Canada House Clinics, the clinic division of Canada House Wellness Group Inc (“Canada House” or the “Company”) (CSE: CHV), is pleased to announce it has entered into a strategic partnership with Peak Pharma Solutions, leveraging its new clinic branding and organizational changes to position itself for accelerated growth.
Canada House Clinics’ superior clinic operation, trusted by physicians for medical cannabis referrals, will be able to access proven pharmaceutical industry sales experts to educate more physicians about the benefits and advantages of referring patients to CHC.
“We are leveraging our national reach to ramp up our growth,” said Canada House Clinics President Alex Kroon. “We selected Peak Pharma Solutions (Peak) based on the vast experience of its senior team in successfully delivering physician detailing programs. We look forward to starting our first physician campaign in a major city market after the holiday season.”
Peak leadership has spent over 20 years implementing sales solutions and managing successful pharmaceutical sales forces. “We are excited to be supporting Canada House Clinics to educate physicians on cannabinoid therapy and why CHC is their best choice,” said Managing Partners Jennifer Meldrum and Richard Adamson. “This program will be on the leading edge for cannabis clinics and will address a key area many physicians struggle with.”
About Canada House Wellness Group Inc.
Canada House is an experienced, integrated medical cannabis company providing patient-specific cannabinoid therapy products and services through its clinics and licensed producer. Canada House is the parent company of Canada House Clinics Inc., Knalysis Technologies and Abba Medix Corp. For more information please visit http://www.canadahouse.ca or www.sedar.com
About Peak Pharma Solutions Inc.
Peak Pharma is a full-service, strategic contract sales organization that provides flexible solutions to healthcare companies at all stages of development. Peak specializes in supporting organizations in the prescription medicine, consumer, medical device and diagnostic space. For more information please visit https://www.peakpharmasolutions.com
For further information, please contact:
Boom Capital Markets
Steve Low
647-620-5101
[email protected]
Canada House Clinics Inc.
Alex Kroon, President
416-624-7887
[email protected]
Peak Pharma Solutions Inc.
Richard Adamson, Managing Partner
Cautionary Statement Regarding Forward Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
